About Sol-Gel Technologies Ltd.
https://www.sol-gel.comSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.
CEO
Moshe Arkin
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-05-05 | Reverse | 1:10 |
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
DELEK GROUP, LTD.
Shares:1.55M
Value:$104.77M
BROADFIN CAPITAL, LLC
Shares:521.82K
Value:$35.37M
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.
Shares:88.46K
Value:$6M
Summary
Showing Top 3 of 7
About Sol-Gel Technologies Ltd.
https://www.sol-gel.comSol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $400K ▼ | $6.69M ▲ | $-5.94M ▼ | -1.49K% ▼ | $-2.13 ▼ | $-5.94M ▼ |
| Q2-2025 | $17.26M ▲ | $6.03M ▲ | $11.61M ▲ | 67.26% ▲ | $4.17 ▲ | $11.23M ▲ |
| Q1-2025 | $1.03M ▲ | $-8.04M ▼ | $-8.81M ▼ | -854.32% ▲ | $-0.32 ▼ | $9.07M ▲ |
| Q4-2024 | $278K ▼ | $6.38M ▲ | $-5.85M ▼ | -2.1K% ▼ | $-0.21 ▼ | $-6.1M ▼ |
| Q3-2024 | $5.36M | $6.19M | $-366K | -6.83% | $-0.01 | $-490K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $20.84M ▼ | $34.59M ▼ | $8.56M ▲ | $26.03M ▼ |
| Q2-2025 | $24.29M ▲ | $39.31M ▲ | $7.42M ▲ | $31.88M ▲ |
| Q1-2025 | $16.9M ▼ | $27.06M ▼ | $6.89M ▼ | $20.17M ▼ |
| Q4-2024 | $23.93M ▼ | $35.85M ▼ | $7M ▼ | $28.85M ▼ |
| Q3-2024 | $28.05M | $42.98M | $8.28M | $34.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2024 | $1.98M ▲ | $0 | $0 | $0 | $0 | $0 |
| Q1-2024 | $-6.34M ▼ | $0 | $0 | $0 | $0 ▲ | $0 |
| Q4-2023 | $-4.84M ▲ | $0 | $0 | $0 | $-6.62M ▼ | $0 |
| Q3-2023 | $-5.71M ▲ | $0 | $0 | $0 | $-1.48M ▼ | $0 |
| Q2-2023 | $-5.97M | $0 | $0 | $0 | $8.81M | $0 |
Revenue by Products
| Product | Q4-2022 | Q2-2022 |
|---|---|---|
 Collabrations | $0 ▲ | $0 ▲ |
 License | $0 ▲ | $0 ▲ |
CEO
Moshe Arkin
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-05-05 | Reverse | 1:10 |
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
DELEK GROUP, LTD.
Shares:1.55M
Value:$104.77M
BROADFIN CAPITAL, LLC
Shares:521.82K
Value:$35.37M
RAYMOND JAMES FINANCIAL SERVICES ADVISORS, INC.
Shares:88.46K
Value:$6M
Summary
Showing Top 3 of 7